Great news to see mild efficacy from a single dose of CAVATAK intravenously but the best part of this announcement is that the second Phase II trial will incorporate the combination treatment of CAVATAK and a chemo drug. I always hoped this would happen as it broadens the use of CAVATAK tremendously.
Looking forward to the markets reactions, although not expecting an NRT reaction by any means